Velpatasvir

Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 2.16 μM[2].

Product Specifications

CAS Number

[1377049-84-7]

Product Name Alternative

GS-5816

UNSPSC

12352005

Hazard Statement

H315, H319, H320

Target

HCV; SARS-CoV

Type

Reference compound

Related Pathways

Anti-infection

Applications

Cancer-programmed cell death

Field of Research

Cancer; Infection; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/Velpatasvir.html

Concentration

10mM

Purity

99.83

Solubility

DMSO : ≥ 100 mg/mL|H2O : < 0.1 mg/mL (ultrasonic; warming)

Smiles

O=C(N([C@H]1C)[C@@H](CC1)C2=NC3=C(C(C=C(OCC4=CC(C5=CN=C([C@H](C[C@H](COC)C6)N6C([C@@H](C7=CC=CC=C7)NC(OC)=O)=O)N5)=CC=C84)C8=C9)=C9C=C3)N2)[C@H](C(C)C)NC(OC)=O

Molecular Formula

C49H54N8O8

Molecular Weight

883.00

Precautions

H315, H319, H320

References & Citations

[1]Lawitz EJ et al. Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein. Antimicrob Agents Chemother. 2016 Aug 22;60 (9) :5368-78.|[2]Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6 (1) :212.|[3]Yasmeen S, et al. An insight into the hepatoprotective role of Velpatasvir and Sofosbuvir per se and in combination against carbon tetrachloride-induced hepatic fibrosis in rats. Environ Sci Pollut Res Int. 2023 Sep;30 (42) :95660-95672.